Immutep Receives A$2.6 Million R&D Tax Incentive From French Government
Portfolio Pulse from Benzinga Newsdesk
Immutep Limited has received a €1.6 million (approximately A$2.6 million) R&D tax incentive payment from the French Government under the Crédit d'Impôt Recherche scheme for eligible R&D activities conducted in the EU during 2022. This follows a previous A$1.13 million cash rebate from the Australian Federal Government for R&D activities in financial year 2022. The funds will support clinical development of eftilagimod alpha and preclinical development of IMP761.
December 07, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immutep Limited received a significant R&D tax incentive from the French Government, which will support its ongoing and planned clinical and preclinical developments.
The receipt of the R&D tax incentive is a positive financial development for Immutep, likely to be viewed favorably by investors. It provides additional resources for the company's research activities without diluting shareholder value. This news could lead to a short-term positive impact on the stock price as it reflects the company's ability to secure non-dilutive funding and the progress of its R&D efforts.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100